Go Pro
LON:GENI

GENinCode Interim Earnings Report

GENinCode logo
GBX 0.85 -0.05 (-5.33%)
As of 11:35 AM Eastern

GENinCode EPS Results

Actual EPS
-GBX 1.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

GENinCode Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

GENinCode Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

GENinCode Earnings Headlines

GENinCode PLC
It’s not about Greenland
The petrodollar arrangement that anchored the US dollar for 50 years quietly expired in June 2024. Since then, China has cut its Treasury holdings by 45% from their peak, and BRICS nations offloaded $47 billion of American debt in a single month. The Trump administration has responded with a $12 billion critical minerals stockpile called Project Vault, equity stakes in miners like MP Materials and Lithium Americas, and a push to secure resources from Greenland to Ukraine. Porter Stansberry lays out the full story in a new documentary, including five companies positioned at the chokepoints of what he calls Trump's New Dollar.tc pixel
AIM Market Roundup: Marechale Capital, Genincode, Boohoo
GENinCode slumps after it reprices options
AIM Market Roundup: Phoenix Copper, Pipehawk, Genincode
See More GENinCode Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like GENinCode? Sign up for Earnings360's daily newsletter to receive timely earnings updates on GENinCode and other key companies, straight to your email.

About GENinCode

GENinCode (LON:GENI) is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide. GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U. GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.

View GENinCode Profile